NV
NVAX.US Novavax Inc
- Market cap
- USD 1.33B
- P/E
- -
- P/B
- 41.23x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NVAX.US undervalued?
Graham numberThe Graham number of Novavax Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Novavax Inc fundamental analysis
No fundamental analysis for Novavax Inc yet.
Novavax Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Novavax Inc
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, a…
Full company profileNovavax Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Novavax Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 15.4M | 31.2M | 34.3M | 18.7M | 476M | 1.15B | 1.60B | 556M | 682M | 1.12B | 353M |
| Gross Profit | -223M | 31.2M | 34.3M | -95.2M | 476M | 1.15B | 696M | 213M | 479M | 1.05B | 261M |
| Operating Income | -269M | -172M | -174M | -121M | -417M | -1.69B | -645M | -567M | -249M | 563M | -135M |
| EBITDA | -261M | -162M | -166M | -113M | -412M | -1.67B | -605M | -487M | -108M | 492M | -86.2M |
| Net Income | -280M | -184M | -185M | -130M | -428M | -1.74B | -658M | -545M | -187M | 440M | -126M |
| EPS | -21 | -13 | -9.99 | -5.40 | -7.43 | -23 | -8.42 | -5.41 | -1.23 | 2.54 | -0.76 |
| Balance Sheet | |||||||||||
| Total Assets | 394M | 302M | 208M | 173M | 1.58B | 2.58B | 2.26B | 1.80B | 1.56B | 1.18B | 888M |
| Total Liabilities | 400M | 404M | 376M | 359M | 955M | 2.93B | 2.89B | 2.51B | 2.18B | 1.30B | 1.10B |
| Shareholders' Equity | -5.55M | -102M | -168M | -186M | 627M | -352M | -634M | -717M | -624M | -128M | -217M |
| Cash & Short-term Investments | 144M | 106M | 70.2M | 78.8M | 711M | 1.52B | 1.34B | 569M | 923M | 735M | 622M |
| Total Debt | 346M | 352M | 344M | 322M | 322M | 454M | 550M | 229M | 230M | 249M | 295M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -255M | -139M | -185M | -137M | -42.5M | 323M | -416M | -714M | -87.3M | -245M | -269M |
| Capital Expenditure | 18.2M | 4.19M | 1.37M | 1.86M | 54.6M | 57.5M | 93.0M | 58.8M | 13.1M | 5.56M | 3.84M |
| Free Cash Flow | -274M | -143M | -186M | -138M | -97.2M | 265M | -509M | -773M | -100M | -250M | -273M |
| Ratios | |||||||||||
| ROE | - | - | - | - | -68.2% | - | - | - | - | - | - |
| ROA | -71.0% | -60.8% | -88.8% | -75.2% | -27.0% | -67.7% | -29.1% | -30.3% | -12.0% | 37.4% | -14.2% |
| Net Profit Margin | -1,823.5% | -589.5% | -538.8% | -697.1% | -89.9% | -152.1% | -41.1% | -98.0% | -27.5% | 39.2% | -35.6% |
| Debt to Equity | - | - | - | - | 0.51x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Novavax Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 39.1M | 0.68 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on May 10, 2019.
Who owns Novavax Inc
- Insiders 5.83%
- Institutions 67.80%
- Public & others 26.37%
- Shares outstanding 165M
- Free float 146M
Top funds holding NVAX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 5.20M | 3.15% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 4.94M | 2.99% | +2.69% | Oct 2026 |
| iShares Russell 2000 ETF | 3.90M | 2.36% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 3.71M | 2.25% | -1.81% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 2.07M | 1.25% | -4.55% | Sep 2026 |
| Fidelity Small Cap Index | 1.67M | 1.01% | 0.00% | Aug 2026 |
| iShares Russell 2000 Value ETF | 1.44M | 0.87% | 0.00% | Oct 2026 |
| Invesco Biotechnology & Genome ETF | 1.23M | 0.74% | 0.00% | Oct 2026 |
| iShares Biotechnology ETF | 1.22M | 0.74% | -0.19% | Oct 2026 |
| PIMCO RAE US S Instl | 1.02M | 0.62% | -21.75% | Jun 2026 |
| Jupiter Merian Glb Eq Abs Rt I USD Acc | 915K | 0.55% | 0.00% | Jun 2026 |
| Vanguard Russell 2000 ETF | 886K | 0.54% | +1.10% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 874K | 0.53% | +0.24% | Oct 2026 |
| Fidelity Enhanced Small Cap Core ETF | 794K | 0.48% | +0.27% | Oct 2026 |
| Federated Hermes MDT Small Cap Core IS | 785K | 0.48% | +26.76% | Sep 2026 |
| Fidelity Extended Market Index | 769K | 0.47% | -5.44% | Sep 2026 |
| First Trust Small Cap Gr AlphaDEX® ETF | 468K | 0.28% | +0.43% | Oct 2026 |
| iShares Genomics Immnlgy & Hlthcr ETF | 452K | 0.27% | 0.00% | Oct 2026 |
| Vanguard Health Care ETF | 428K | 0.26% | +0.11% | Sep 2026 |
| LVIP FranklinTempletonMltFctSMIDCapEqStd | 407K | 0.25% | 0.00% | Sep 2026 |
Top institutions holding NVAX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 13.9M | 8.45% | +8.58% | Jun 2026 |
| Shah Capital Management | 12.2M | 7.38% | -14.06% | Sep 2026 |
| State Street Corp | 11.7M | 7.12% | +30.88% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 7.61M | 4.61% | +6.38% | Jun 2026 |
| Vanguard Capital Management, LLC | 7.26M | 4.40% | +1.79% | Jun 2026 |
| Sanofi | 6.88M | 4.17% | 0.00% | Sep 2026 |
| D. E. Shaw & Co LP | 5.65M | 3.42% | -26.71% | Jun 2026 |
| Geode Capital Management, LLC | 4.21M | 2.55% | +7.93% | Jun 2026 |
| Two Sigma Investments LLC | 4.09M | 2.48% | +565.43% | Jun 2026 |
| Coatue Management LLC | 3.84M | 2.33% | 0.00% | Jun 2026 |
| Bank of America Corp | 3.42M | 2.07% | -48.53% | Jun 2026 |
| The Goldman Sachs Group Inc | 3.01M | 1.82% | +113.40% | Jun 2026 |
| UBS Group AG | 1.87M | 1.13% | -58.25% | Jun 2026 |
| Millennium Management LLC | 1.77M | 1.07% | -54.10% | Jun 2026 |
| Citadel Advisors Llc | 1.70M | 1.03% | +50.86% | Jun 2026 |
| Allianz Asset Management AG | 1.58M | 0.96% | -15.09% | Jun 2026 |
| Northern Trust Corp | 1.45M | 0.88% | -4.06% | Jun 2026 |
| TSP Capital Management Group/LLC | 1.43M | 0.87% | +0.92% | Sep 2026 |
| Charles Schwab Investment Management Inc | 1.35M | 0.82% | -1.96% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 1.09M | 0.66% | -1.99% | Jun 2026 |
Novavax Inc company profile
- Company name
- Novavax Inc
- Ticker
- NVAX.US
- Exchange
- USA Stocks
- Listed since
- Dec 5, 1995
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 749
- Fiscal year end
- December
- Address
- 21 Firstfield Road, Gaithersburg, MD, United States, 20878
- Phone
- 240 268 2000
- Website
- novavax.com
About Novavax Inc
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Novavax Inc management
10- Mr. John Charles Jacobs M.B.A.President, CEO & Director · born 1967
- Mr. James Patrick Kelly C.F.A.Executive VP, CFO & Treasurer · born 1966
- Mr. Mark J. Casey Esq., J.D.Executive VP, Chief Legal Officer & Corporate Secretary · born 1963
- Ms. Elaine O'HaraExecutive VP & Chief Strategy Officer · born 1968
- Mr. Richard P. CrowleyExecutive VP & COO · born 1957
- Ms. Naina ZamanDirector of Investor Relations
- Mr. Troy Morgan Esq., J.D.Senior VP, Deputy General Counsel & Chief Compliance Officer · born 1971
- Ms. Erika S. TrahanAssociate Director of Investor & Public Relations
- Mr. Ian J. WatkinsExecutive VP & Chief Human Resources Officer · born 1963
- Ms. Silvia Taylor M.B.A.Executive VP, Chief Corporate Affairs Officer & Head of Novavax Sweden